AzTrials
AzTrials

Acute StrokePhase 3ESTRELNCT03735901

Enhancement of Stroke Rehabilitation With Levodopa

A Phase 3 study testing IMP Levodopa 100mg/Carbidopa 25mg in people with Acute Stroke and Stroke Rehabilitation, run by University Hospital, Basel, Switzerland at 24 sites in Switzerland.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Stroke, Stroke Rehabilitation
What is being tested?
IMP Levodopa 100mg/Carbidopa 25mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
610 participants
Where
24 sitesSwitzerland
Study dates
14 Jun 2019to 30 Jun 2029
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Acute ischemic or hemorrhagic (i.e. intracerebral hemorrhage excluding subarachnoid hemorrhage and cerebral venous sinus thrombosis) stroke ≤ 7 days prior to randomization
  • Clinically meaningful hemiparesis (i.e. scoring a total of ≥ 3 points on the following NIH stroke scale score items (i) motor arm, (ii) motor leg, (iii) limb ataxia; a distal arm paresis is equivalent to one of the aforementioned (i-iii))
  • Time of randomization ≥24-hours since thrombolysis or thrombectomy
  • In-hospital rehabilitation required
  • Capable to participate in standardized rehabilitation therapy
  • Informed consent of patient or next of kin

Who cannot join

  • Diagnosis of Parkinson's Disease
  • Use of Levodopa mandatory according to judgement of treating physician
  • Inability or unwillingness to comply with study procedures including adherence to study drug intake (orally, or via nasogastric tube or percutaneous endoscopic gastrostomy tube)
  • Severe aphasia (i.e. unable to follow two-stage-commands)
  • Previously dependent in the basal activities of daily living (defined as modified Ranking Scale prior to stroke > 3)
  • Pre-existing hemiparesis
Show all 9Show fewer
  • Known hypersensitivity to Levodopa/Carbidopa and other contraindications for Levodopa/Carbidopa as outlined in the summary of product characteristics
  • Women who are pregnant or breast feeding, or who intend to become pregnant during the course of the study. Women of childbearing age must take a pregnancy test to be eligible for the study.
  • Lack of safe contraception, defined as: Female Participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the Investigator in individual cases. Female Participants who are surgically sterilized / hysterectomized or post- menopausal for longer than 2 years are not considered as being of child- bearing potential.

Trial locations and contacts

24 sites in 1 country.

24 sites in 1 country

Switzerland24 sites
  • Kantonsspital Aarau, Neurozentrum

    Aarau, 5001

  • RehaClinic AG

    Bad Zurzach, 5330

  • Kantonsspital Baden

    Baden, 5404

  • Felix Platter Spital

    Basel, 4002

  • Stroke-Center Universitätsspital Basel

    Basel

  • Inselspital, Universitätsklinik für Neurologie

    Bern, 3010

  • Kantonsspital Graubünden, Departement Innere Medizin / Neurologie

    Chur, 7000

  • HFR Fribourg Hopital Cantonal, U. de Neurologie

    Fribourg, 1708

  • Centre hospitalier universitaire vaudois, Service de Neurologie

    Lausanne, 1011

  • HFR Meyriez-Murten, Clinique de Réhabilitation

    Meyriez, 3280

  • Kantonsspital Münsterlingen

    Münsterlingen, 8596

  • Reha Rheinfelden

    Rheinfelden, 4310

  • Kantonsspital St.Gallen, Klinik für Neurologie

    Sankt Gallen, 9007

  • Hôpital du Valais - Sion, Service de neurologie

    Sion, 1950

  • Hôpital du Valais - Sion

    Sion, 1950

  • Rehazentrum Valens, Klinik für Neurologie und Neurorehabilitation

    Valens, 7317

  • Cereneo Schweiz AG

    Vitznau, 6354

  • Zürcher RehaZentrum Wald

    Wald, 8636

  • Rheinburg Klinik AG

    Walzenhausen, 9428

  • Kantonsspital Winterthur

    Winterthur, 8401

  • Rehaklinik Zihlschlacht

    Zihlschlacht, 8588

  • Klinik Lengg AG

    Zurich, 8008

  • Head Stroke Center Klinik Hirslanden

    Zurich, 8032

  • Universitätsspital Zürich, Klinik für Neurologie

    Zurich, 8091

Other trials in Switzerland

About this study

Official title: Enhancement of Stroke Rehabilitation With Levodopa (ESTREL): a Randomized Placebo-controlled Trial

Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Study participants will be randomized 1:1.

Read the detailed description

Trial investigates whether Levodopa/Carbidopa compared to placebo given in addition to standardized rehabilitative therapy in patients with acute stroke is associated with

  1. patient relevant improvements of physical function b) improvement in patient-self assessed general health aspects, pain, mood, anxiety, fatigue and social participation c) long-term sustainability of a patient-relevant improvement of motor function d) improvement of selective hand and wrist movement e) a higher rate of patients walking independently of the help of another person.
  2. less severe impairment g) a higher level of activity of daily living h) improvements of quality of life (i) better cognitive performance (j) no signals of harms (i.e. indications for increased all-cause mortality, recurrent stroke, serious adverse events, and non-serious, pre-specified adverse events possibly related to the IMP)

Estrel-Longterm: optional prolongation of the observational study phase. To investigate the long-term outcomes of our study population the investigator aim to offer an optional prolongation of the observational phase to the participants through regular structured (once yearly) telephone visits.

The telephone visits will be carried out annually for the following 4 years.

Being tested
IMP Levodopa 100mg/Carbidopa 25mg, Matching placebo
Keywords
Levodopa / Carbidopa, Fugl-Meyer-Motor-Assessment (FMMA), Acute ischemic stroke, Acute hemorrhagic stroke, Rehabilitation, Recovery, Randomized controlled trial
Medical subject headings
Stroke, Ischemic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IMP Levodopa 100mg/Carbidopa 25mgDrug

    Study treatment will comprise 3 phases:

    1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;
    2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).
    3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
  • Matching placeboDrug

    Study treatment will comprise 3 phases:

    1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;
    2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).
    3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study groups in NCT03735901
Study groupRoleWhat they receive
Experimental InterventionActive comparatorWhite Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
Receives: Drug: IMP Levodopa 100mg/Carbidopa 25mg
Control InterventionPlacebo comparatorMatching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
Receives: Drug: Matching placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fugl-Meyer-Motor Assessment Score (FMMA)

    FMMA is a stroke-specific impairment index designed to assess motor recovery. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale (0=cannot perform; 1=performs partially and 2= performs fully). FMMA total scores range from 0 (no movements) to 100 (normal movements) with 66 points for movements of the upper limbs (FMMA-UE) and 34 for those of the lower limbs (FMMA-LE). A difference of 5.25 points for the upper extremity and 6 points for the lower extremity part of the score are described as minimal clinically important difference. For this study, based on these data, 6 points difference are considered a patient-relevant difference between both treatment groups for the primary endpoint.

    Measured: Assessed 3 months +/- 14 days after randomization

Secondary outcomes (20)
  1. NIH-Stroke Scale Score (NIHSS)

    To objectively quantify the impairment caused by a stroke. NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For this study, an extra item for distal arm paresis was included (score from 0-2). For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (+4 for distal arm paresis), with the minimum score being a 0.

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  2. Modified Rankin Scale Score (mRS)

    Scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.

    0 - No symptoms.

    1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
    2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
    3. - Moderate disability. Requires some help, but able to walk unassisted.
    4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
    5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
    6. - Dead.

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization

  3. Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 29

    Patient-self-assessment in the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity. Each of the domains 1 to 7 are assessed with 4 questions. Items are scored on 1 of 5 levels based on the ability of the participant to perform activities or the self-assessment of the participant in the various domains. Pain intensity is scored on a visual analogue scale of 0 to 10.

    Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  4. Stroke rehabilitation outcomes for disease specific morbidity and quality of life - PROMIS 10

    Patient-self-assessment Patient-Reported Outcomes Measurement Information System (PROMIS) 10 addresses general health aspects, quality of life, pain, mood, anxiety, fatigue and social participation; PROMIS-10 covers the outcome domains considered most important

    Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization

  5. Patient-reported assessment of relevance of motor improvement

    Patients Questionnaire asking whether there is improvement in motor function since the last study visit and if so, whether this improvement is relevant in patients' personal perception (yes/ no).

    Measured: Assessed 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization

  6. Rivermead Mobility Index (RMI)

    15 items that measure the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. between bed to chair), walk, and use stairs and is scored from 0-15 Points. A RMI score of ≥ 7 translates into the ability of the patient walking independently of the assistance of another Person.

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization

  7. Mortality (of any cause)

    death rate

    Measured: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization

  8. Recurrent stroke (any type)

    recurrent stroke (any type)

    Measured: Throughout the whole study period from Day 1 to Visit 12/24/36/48/60 months +/- 30 days after randomization

  9. Pre- specified Adverse Events of Interest

    Nausea, Vomiting, Taste disturbances, Dry mouth, Anorexia, Arrhythmias, Postural hypotension Syncope (unconsciousness for a short time as a result of reduced blood flow to the brain), drowsiness (including sudden onset of sleep) Fatigue, Dementia, Psychoses (a distorted perception of reality), Hallucinations, Confusion, Euphoria, Abnormal dreams, Insomnia, Depression, Anxiety, Dizziness, Dystonia (involuntary contractions), Dyskinesia (inability to control voluntary movements), Chorea (sudden twitching of the face and shoulders)

    Measured: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)

  10. Motricity Index (MI)

    Two subscales, one for the upper extremity (UE) (total score range 0 to 100) and one for the lower extremity (LE) (total score range 0 to 100). It measures isometric muscle strength (0 = no movement; 100 = normal)

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  11. Trunk Control Test (TCT)

    Assesses the trunk abilities of the patient , contains 4 items, with item scores ranging from 0 to 25. The sitting balance item assesses the patients' ability to sit during 30 seconds without trunk and feet support and has a predictive value for recovery of walking poststroke

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  12. Action Research Arm Test (ARAT)

    Assesses the patients' ability to grasp (subscale with 6 items), grip (subscale with 4 items), pinch (subscale with 6 items) and perform gross movements (subscale with 3 items) with the upper extremity. Score: 0 = no movement / 1= movement task is partially performed / 2 = movement task is completed but takes abnormally long / 3 = movement is performed normally

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  13. Box- and Block Test (BBT)

    Patients (seated in front of a square box with two compartments) are asked to move as many wooden cubes as possible from one compartment to the other within 60 seconds of testing time.

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  14. Functional Ambulation Categories (FAC)

    Classification (score range 0 to 5) regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account.

    Rating:

    0 = Patient cannot walk, or needs help from 2 or more persons

    1. = Patient needs firm continuous support from 1 person who helps carrying weight and with balance
    2. = Patient needs continuous or intermittent support of one person to help with balance and coordination
    3. = Patient requires verbal supervision or stand-by help from one person without physical contact
    4. = Patient can walk independently on level ground, but requires help on stairs, slopes or uneven surfaces
    5. = Patient can walk independently anywhere

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12/24/36/48/60 months +/- 30 days after randomization

  15. Ten-Meter Walk Test (10MWT)

    Walking speed and cadence over a 10 meter track at both a comfortable and a maximum Speed; time in seconds over 10-meter walking distance

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  16. Jamar dynamometer testing (JDT)

    grip strength and strength of the forearm (in kilogram)

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  17. Montreal Cognitive Assessment (MoCA)

    Assesses cognitive domains: Short-term memory recall task (5 points).Visuospatial abilities assessed using clock-drawing task (3 points) and 3-dimensional cube copy (1 point). Executive functions assessed using alternation task. Attention, concentration, working memory evaluated using a sustained attention task (target detection using tapping; 1 point), serial subtraction task (3 points), digits forward and backward (1 point each). Languages assessed using 3-item confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), repetition of 2 complex sentences (2 points), and fluency task. Orientation to time and place evaluated by asking for date and city in which the test is occurring (6 points). A score of 26 or over is considered to be normal (range 0 to 30)

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  18. Daily activity measurement with movement sensor

    Movement sensors allow assessment of physical activity engagement and upper limb use in daily life situations without physically hampering the patient in the performance of their daily activities

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 3 months +/- 14 days after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

  19. Serious Adverse Event (SAE)

    Any untoward medical occurrence that:

    • results in death,
    • is life-threatening,
    • requires in-patient hospitalization or prolongation of existing hospitalisation,
    • results in persistent or significant disability/incapacity, or
    • is a congenital anomaly/birth defect

    Measured: Throughout the study period from Day 1 to Visit 3 ( 3 months +/- 14 days after randomization)

  20. Fugl-Meyer-Motor Assessment Score (FMMA)

    FMMA is a stroke-specific impairment index designed to assess motor recovery. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale (0=cannot perform; 1=performs partially and 2= performs fully). FMMA total scores range from 0 (no movements) to 100 (normal movements) with 66 points for movements of the upper limbs (FMMA-UE) and 34 for those of the lower limbs (FMMA-LE). A difference of 5.25 points for the upper extremity and 6 points for the lower extremity part of the score are described as minimal clinically important difference. For this study, based on these data, 6 points difference are considered a patient-relevant difference between both treatment groups for the primary endpoint.

    Measured: Assessed at Day 0 (Randomization), 5 weeks after randomization, 6 months +/- 20 days after randomization and 12 months +/- 30 days after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2018
  2. Study start14 Jun 2019
  3. Primary completion27 Aug 2024
  4. Study completion30 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Study participants will be randomized 1:1
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
610 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03735901
Sponsor's protocol ID
2018-02021; me16Engelter
Other IDs
2018
Acronym
ESTREL
Status last verified
Oct 2024
First submitted
7 Nov 2018
Last updated
15 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Trussel S, Traenka CK, Polymeris A, Enz L, Zietz A, Altersberger VL, Wiesner K, Katan M, Lyrer PA, Goga I, Engelter S, Luft AR, Rottenberger Y, Schwarz A, Medlin F, Muri RM, Seiffge D, Fischer U, Michel P, Peters N, Kagi G, Politz S, Tarnutzer A, Nedeltchev K, Bonati L, Schuster-Amft C, Moller JC, Bujan B, Sandor PS, Gonzenbach R, Mylius V, Lienert C, Held J, Schaedelin S, Hemkens LG, Ford GA, Kaufmann JE, Gensicke H, Engelter ST. Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial. Eur Stroke J. 2026 Jul 6;11(7):aakag089. doi: 10.1093/esj/aakag089.

    PubMed 42525438
  • Sauter MI, Kaufmann JE, Boos L, Zietz A, Trussel S, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Arnold M, Nedeltchev K, Schar J, Deglon KVDK, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C, Engelter ST. The impact of levodopa on post-stroke depression: the ESTREL-depression-study. Eur Stroke J. 2026 Feb 9;11(2):aakag001. doi: 10.1093/esj/aakag001.

    PubMed 41701756
  • Engelter ST, Kaufmann JE, Zietz A, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kagi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Fischer U, Nedeltchev K, Schar J, Van Den Keybus Deglon K, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gaumann S, Chabwine JN, Humm A, Moller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Muri RM, Schadelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C; ESTREL Investigators. Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial. JAMA. 2025 Nov 4;334(17):1523-1532. doi: 10.1001/jama.2025.15185.

    PubMed 40982270

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing IMP Levodopa 100mg/Carbidopa 25mg in people with Acute Stroke and Stroke Rehabilitation, run by University Hospital, Basel, Switzerland at 24 sites in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fugl-Meyer-Motor Assessment Score (FMMA) (time frame: Assessed 3 months +/- 14 days after randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03735901, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in